Business Wire

VA-SES

1.8.2022 16:30:07 CEST | Business Wire | Press release

Share
SES Completes $450 Million Acquisition of DRS Global Enterprise Solutions Doubling US Government Business

SES and its wholly-owned subsidiary SES Government Solutions (SES GS) today announced the completion of the acquisition of DRS Global Enterprise Solutions (GES) from Leonardo DRS for $450 million after obtaining all the necessary regulatory approvals. The DRS GES business will be combined with SES GS to create a scaled solutions provider serving the multi-orbit satellite communications needs of the US Government and supporting missions anywhere on land, at sea, or in the air.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005477/en/

With the combined businesses operating as SES Government Solutions, the new organization will comprise a cross-functional workforce with deep technical expertise and a proven ability to integrate and manage multi-orbit geostationary and medium earth orbit (MEO) services as well as multi-operator network solutions. In particular, SES GS will offer highly flexible second-generation MEO services – via SES’s soon-to-be launched O3b mPOWER system – with a unique combination of low latency and high throughput per terminal for high-value missions, to an expanded government customer base. SES GS will also leverage essential tools and expertise in cybersecurity operations, customer support, governance and compliance. The combined business will continue to serve US Government customers under the direction of the SES GS Proxy Board of Directors.

The consolidation of DRS GES with SES GS is expected to unlock $25 million of annualized run-rate synergies, with government becoming SES’s largest data business segment in terms of revenue.

The combined business will be led by David Fields, who assumes responsibilities on August 1, 2022 as appointed by the SES GS Proxy Board. Fields has over 30 years of experience in the satellite communications and information technology (IT) services industries, and joins SES GS from DRS GES. He succeeds Brigadier General Pete Hoene, USAF (Retired), who, after 11 years at the helm of SES GS and decades of dedicated service in the satellite communications arena, will take his retirement.

“I am extremely excited about the potential that this combination unleashes, reinforcing our commitment to provide best-in-class satellite network solutions to the US Department of Defense customers,” said Brigadier General Billy Bingham, USAF (Retired), Chairman of the SES GS Proxy Board. “We are delighted to welcome Fields, who comes to SES GS with extensive knowledge and expertise in the satellite communications industry and a demonstrated record of achievement in the US Government sector. Well-respected by industry partners and customers, he has developed deep and trusted relationships with many US Government agencies, and we anticipate David to build on his success through his leadership of the combined business. We would also like to take this opportunity to thank Pete Hoene, whose leadership has resulted in SES GS achieving outstanding growth rate of over 30% in just the last five years. We wish him all the best in his well-earned retirement.”

“I am excited to join SES GS and honored to lead the combined team where we will be delivering best-in-class solutions and state-of-the-art multi-orbit satellite networking capabilities,” said David Fields, President and CEO of SES GS. “SES GS will be significantly expanding its differentiated value proposition for the US Government, with a trusted multi-operator network integration and service management solutions. The breadth of our capabilities, now spanning both connectivity and integration, allows for building, managing and supporting the most advanced satellite networks solutions for our US Government customers.”

Follow us on:

Twitter | Facebook | YouTube | LinkedIn | Instagram

Read our Blogs >
Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over ~8,200 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

About SES Government Solutions

SES Government Solutions (SES GS) is a wholly-owned subsidiary of SES, the leader in global content connectivity solutions, and is exclusively focused on building, managing, and supporting the most advanced satellite network solutions for the US Government. SES GS leverages a proven multi-operator network integration and management capability, an extensive global terrestrial network, as well as access to SES’s multi-orbit satellite fleet. It also offers US Department of Defense customers the essential tools in cybersecurity for mission-critical operations, coupled with a proven track record in governance and compliance. SES GS operates under a proxy board, enabling it to support classified projects, and it has been present in the US Government satcom market for over four decades. Further information can be found at: www.ses-gs.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye